IFPMA: Pharmaceutical Industry Expresses Deep Disappointment With Decision on Waiving Intellectual Property Rights Adopted at the World Trade Organization Ministerial Conference
IFPMA, the body representing biopharmaceutical companies in Geneva, expresses deep disappointment with the decision taken to adopt a TRIPS waiver, despite intellectual property (IP) not being a barrier to vaccine scale-up and wide acknowledgment of vaccines surplus. IP has enabled the rapid research and development of several effective vaccines against COVID-19 and underpinned the more … [Read more…]
